BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM. This compound is a valuable research tool for investigating the role of ET-1 signaling in cardiovascular diseases, pulmonary hypertension, and cancer, as demonstrated in various in vitro and in vivo studies. It has been evaluated in Phase 2 clinical trials.